Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNKSR1 siRNA
- Development stage
- Preclinical
- Lead developer
- PHusis Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
CNKSR1 siRNA is a small interfering RNA designed to silence the expression of the Connector Enhancer of Kinase Suppressor of RAS 1 (CNKSR1) protein. CNKSR1 is a scaffold protein located in the RAS membrane signaling nanocluster, where it facilitates mutant KRAS signaling. By knocking down CNKSR1, the siRNA selectively inhibits the growth and signaling of mutant KRAS-driven cancer cells, such as non-small cell lung cancer (NSCLC) and pancreatic cancer, while sparing cells with wild-type KRAS. This approach targets the dependency of oncogenic KRAS on the CNKSR1 scaffold for its downstream proliferative effects. In research settings, it has been used to validate CNKSR1 as a druggable target for small molecule development.
- Other names
- CNKSR1-targeting siRNACNKSR-1-targeting siRNACNKSR 1-targeting siRNAsiRNA knockdown of CNKSR1
02
Targets
Connector enhancer of kinase suppressor of ras 1 mRNA
Beyond the preview
Go deeper on CNKSR1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNKSR1 siRNA.